[Articles] Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial

AI Summary

A randomised trial in adolescents with HIV in sub-Saharan Africa found that long-acting injectable cabotegravir–rilpivirine given every eight weeks was superior to TLD for maintaining viral suppression. No new safety concerns were observed, supporting the injectable combination as a maintenance treatment option for this population.

In adolescents with HIV with virological suppression, LAI cabotegravir–rilpivirine was superior to TLD for maintaining virological suppression, with no new safety concerns observed. These findings support LAI cabotegravir–rilpivirine as a maintenance treatment option for this population.